Group 1 - The domestic animal health industry is experiencing structural adjustments, with sales growth slowing to 3.7% from 2020 to 2023 and gross profit declining by 3.2% [1] - The "Matthew effect" is intensifying, leading to increased pressure on small and medium-sized animal health companies, while leading firms are expected to gain larger market shares through diverse product matrices, continuous R&D investment, and improved after-sales service [1] - The average gross profit per head for self-breeding pig farming is projected to improve significantly to 170 yuan in 2024, with leading companies like Muyuan Foods and Wens Foodstuffs reporting substantial profit increases [2] Group 2 - The pet medical market is expected to reach approximately 840 billion yuan in 2024, driven by rising health awareness among pet owners and increasing demand for disease prevention and treatment [3] - Domestic animal health companies' sales of pet and other biological products currently account for only 6.0% of the market, but this is expected to accelerate with the introduction of domestic vaccines and deworming drugs [3] - The export of innovative pet drugs is anticipated to become a significant breakthrough for domestic animal health companies, with notable products like "Hailiwang" marking substantial progress in international markets [3] Group 3 - Some listed animal health companies are experiencing declining performance due to disordered competition, while others are achieving revenue growth through integrated strategies [2] - The importance of product and technological innovation is highlighted as a key factor for success in the industry [2] - Companies to watch include Ruipu Biological, Kexin Biological, Huisheng Biological, and others, indicating potential investment opportunities in the sector [4]

Core Viewpoint - Qingdao Weilan Biological Co., Ltd. has obtained a new veterinary drug registration certificate for "Prednisolone Tablets," marking a significant advancement in the treatment of canine allergic and inflammatory diseases [1][2]. Group 1: New Veterinary Drug Information - The new veterinary drug, "Prednisolone Tablets," is classified as a Category V new veterinary drug and is approved for treating allergic and inflammatory diseases in dogs, including non-specific eczema, summer dermatitis, and allergic conditions [2][3]. - The drug is developed by a consortium of companies, including Qingdao Weilan Biological Co., Ltd. and its subsidiaries, with a total research and development investment of 1.7444 million yuan [2][3]. Group 2: Market Background - Skin diseases have the highest incidence among pet diseases, particularly in dogs, with recurrent skin conditions accounting for over 75% of total incidence rates [2][3]. - There is a limited variety of drugs available for treating inflammatory skin diseases in pets, primarily relying on glucocorticoids, which have significant side effects and metabolic burdens [3][4]. Group 3: Drug Development and Impact - Prednisolone is a modified glucocorticoid with four times the anti-inflammatory activity of hydrocortisone and reduced sodium retention, making it suitable for animals with liver dysfunction [3][4]. - The approval of the new veterinary drug reflects the company's commitment to technological innovation and is expected to create new growth opportunities for the business [4].